JAMA Netw Open
COVID-19 mRNA vaccination tied to lower 4-year mortality
A French national cohort study of 28.7 million adults aged 18 to 59 compared 4-year all-cause mortality between those vaccinated with an mRNA COVID-19 vaccine and unvaccinated peers. Among 22.8 million vaccinated and 5.9 million unvaccinated individuals followed for a median of 45 months, vaccinated participants had a 25% lower risk of all-cause death (weighted hazard ratio [wHR], 0.75) and a 74% lower risk of death from severe COVID-19 (wHR, 0.26). Sensitivity analyses excluding COVID-related deaths showed similar results, and short-term mortality within 6 months post-vaccination was also lower.
Clinical takeaway: mRNA COVID-19 vaccination in adults aged 18 to 59 wasn't associated with increased long-term mortality, further supporting the safety of mRNA vaccines that are widely used worldwide.
Source:
Semenzato L, et al. (2025, December 1). JAMA Netw Open. COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France. https://pubmed.ncbi.nlm.nih.gov/41343214/